Levetiracetam Actavis

Levetiracetam, the active ingredient in Levetiracetam Actavis, is an anticonvulsant presented as an oral tablet for oral administration. It is indicated for the management of epilepsy, specifically for partial‑onset seizures and generalized tonic‑clonic seizures in adult and pediatric patients, and is commonly prescribed in clinical practice.

GNH USA supplies Levetiracetam Actavis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, sourcing the product from EU‑regulated manufacturers and providing regulatory‑approved documentation for global distribution.

Levetiracetam is used to control seizure activity in several epilepsy syndromes. - Partial (focal) seizures: reduces the frequency of seizure episodes in patients with focal onset epilepsy. - Generalized tonic‑clonic seizures: helps achieve seizure freedom or reduction in adults and adolescents. - Myoclonic seizures: may be employed as adjunct therapy to control myoclonic episodes in appropriate patients.

Levetiracetam may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Fatigue: feeling of tiredness or reduced energy. - Headache: mild to moderate cranial pain. - Irritability: mood changes including increased agitation.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or difficulty breathing. - Mood disorders: depression, suicidal thoughts, or aggressive behavior. - Hematologic abnormalities: low blood cell counts such as leukopenia or thrombocytopenia.

When prescribing levetiracetam, clinicians should consider several precautionary measures to ensure safe use. - Renal impairment: adjust dose based on creatinine clearance. - Hepatic dysfunction: monitor liver function tests periodically. - Psychiatric history: observe for new or worsening mood changes. - Concomitant CNS depressants: use caution as additive sedation may occur. - Pregnancy and lactation: evaluate risk‑benefit, as safety data are limited. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Levetiracetam can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Carbamazepine: may reduce levetiracetam plasma levels, decreasing seizure control. - Phenobarbital: can lower levetiracetam concentrations, requiring dose adjustment.

Moderate Interactions (Monitor Closely): - Valproic acid: may increase levetiracetam levels, monitor for toxicity. - Other antiepileptic drugs (e.g., phenytoin, lamotrigine): may require therapeutic monitoring. - Oral contraceptives: levetiracetam may reduce hormonal efficacy, advise alternative contraception.